With more than 1 billion people worldwide living with some type of chronic pain, a large unmet medical need for safe and effective analgesics exists. Traditional non-steroidal anti-inflammatory drugs (NSAIDs) are the most widely used drugs to treat pain and inflammation associated with osteoarthritis, but their use is limited by adverse effects on gastrointestinal and platelet function, as well as increased cardiovascular liability. Levicept Ltd is an UK based biotechnology company developing a novel, safe and efficacious biological therapy (p75NTR-Fc) for the treatment of chronic pain: including osteoarthritis and neuropathic pain. Our plans are to develop p75NTR-Fc and test its efficacy and safety in Phase I clinical trials in OA patients.